XML 84 R69.htm IDEA: XBRL DOCUMENT
v3.22.1

Government Contracts - Additional Information (Detail) |  | 1 Months Ended | 12 Months Ended | 24 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 01, 2019 USD ($) | May 31, 2021 USD ($) Option | Jul. 31, 2018 USD ($) | Feb. 28, 2018 USD ($) | Feb. 28, 2017 USD ($) | Jun. 30, 2016 USD ($) Option | Dec. 31, 2021 USD ($) Option | Dec. 31, 2020 USD ($) | Feb. 28, 2019 | Jan. 19, 2022 USD ($) | Jan. 31, 2020 USD ($) | May 31, 2019 USD ($)
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  | $ 18,256,000 | $ 9,330,000 |  |  |  |
BARDA and DTRA [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential funding from government contract |  |  |  |  |  |  | 9,700,000 |  |  |  |  |
BARDA and Speros Achievement of Specified Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential grant amount exercised |  |  |  |  |  |  | 12,700,000 |  |  |  |  |
Grant [Member] | Maximum [Member] | DoD, CDMRP and JWMRP [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  | 4,500,000 | 400,000 |  |  |  |
SPR206 [Member] | DoD, CDMRP and JWMRP [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Award received for clinical development | $ 5,900,000 |  |  |  |  |  |  |  |  |  |  |
Non-dilutive funding period | 4 years |  |  |  |  |  |  |  |  |  |  |
BARDA [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential contract amount awarded |  |  | $ 44,200,000 |  |  |  |  |  |  | $ 59,700,000 |  |
Potential amount additional funding awarded |  |  |  |  |  |  |  |  |  | 12,900,000 |  |
Overall potential award increased |  |  |  |  |  |  |  |  |  | $ 46,900,000 |  |
BARDA [Member] | Base Period Contracts [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential amount initial funding awarded |  |  | $ 15,700,000 |  |  |  |  |  |  |  |  | $ 18,200,000
Potential amount additional funding awarded |  |  |  |  |  |  |  |  |  |  |  | 2,500,000
Overall potential award increased |  |  |  |  |  |  |  |  |  |  |  | $ 46,800,000
Contract term |  |  | 3 years |  |  |  |  |  |  |  |  |
BARDA [Member] | Grant [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  | 9,900,000 | 7,900,000 |  |  |  |
BARDA [Member] | First Option [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential amount additional funding awarded |  |  |  |  |  |  |  |  |  |  | $ 15,900,000 |
Potential amount increase in committed funding |  |  |  |  |  |  |  |  |  |  | 34,000,000.0 |
BARDA [Member] | Second Option [member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential grant amount awarded |  |  |  |  |  |  |  |  |  |  | $ 12,700,000 |
DTRA [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential amount additional funding awarded |  |  |  |  |  |  | 10,000,000.0 |  |  |  |  |
Niaid [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract term |  |  |  |  | 12 months |  |  |  | 2 years |  |  |
Grant revenue |  |  |  |  |  |  | 0 | 100,000 |  |  |  |
Niaid [Member] | Spero Cantab [Member] | Cantab Anti Infectives Ltd. [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential funding from government contract |  |  |  |  |  | $ 6,500,000 |  |  |  |  |  |
Number of option period for funding from government contract | Option |  |  |  |  |  | 3 |  |  |  |  |  |
Niaid [Member] | Base Period Contracts [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Potential grant amount awarded |  |  |  |  | $ 600,000 |  |  |  |  |  |  |
Niaid [Member] | Grant [Member] | Spero Cantab [Member] | Cantab Anti Infectives Ltd. [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  | $ 400,000 | $ 700,000 |  |  |  |
Niaid [Member] | SPR206 [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract term |  | 5 years |  |  |  |  |  |  |  |  |  |
Award received for clinical development |  | $ 23,400,000 |  |  |  |  |  |  |  |  |  |
Number of option period for funding from government contract | Option |  | 5 |  |  |  |  |  |  |  |  |  |
Committed amount from government contract |  | $ 2,100,000 |  |  |  |  |  |  |  |  |  |
Maximum received fund |  | $ 400,000 |  |  |  |  |  |  |  |  |  |
Niaid [Member] | Option Period Contracts [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Contract term |  |  |  | 12 months |  |  |  |  |  |  |  |
Potential grant amount awarded |  |  |  |  | $ 400,000 |  |  |  |  |  |  |
Potential grant amount exercised |  |  |  | $ 400,000 |  |  |  |  |  |  |  |
Niaid [Member] | First Option [Member] | Spero Cantab [Member] | Cantab Anti Infectives Ltd. [Member] | Cantab Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |
Government Contracts [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of option period for funding from government contract | Option |  |  |  |  |  |  | 2 |  |  |  |  |
Committed amount from government contract |  |  |  |  |  |  | $ 5,900,000 |  |  |  |  |

X
- Definition Award received for research and development. + References No definition available. + Details
Name: | spro_AwardReceivedForResearchAndDevelopment
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract term. + References No definition available. + Details
Name: | spro_ContractTerm
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Covering period of non-diluitve funding. + References No definition available. + Details
Name: | spro_CoveringPeriodOfNonDiluitveFunding
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Government contracts. + References No definition available. + Details
Name: | spro_GovernmentContractsLineItems
Namespace Prefix: | spro_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase in overall potential award. + References No definition available. + Details
Name: | spro_IncreaseInOverallPotentialAward
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum potential funding from government contract + References No definition available. + Details
Name: | spro_MaximumPotentialFundingFromGovernmentContract
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum received fund amount. + References No definition available. + Details
Name: | spro_MaximumReceivedFundAmount
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of option period for funding from government contract. + References No definition available. + Details
Name: | spro_NumberOfOptionPeriodForFundingFromGovernmentContract
Namespace Prefix: | spro_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential amount additional funding awarded. + References No definition available. + Details
Name: | spro_PotentialAmountAdditionalFundingAwarded
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential amount increase in committed funding. + References No definition available. + Details
Name: | spro_PotentialAmountIncreaseInCommittedFunding
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential amount initial funding awarded. + References No definition available. + Details
Name: | spro_PotentialAmountInitialFundingAwarded
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential contract amount awarded. + References No definition available. + Details
Name: | spro_PotentialContractAmountAwarded
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential grant amount awarded. + References No definition available. + Details
Name: | spro_PotentialGrantAmountAwarded
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential grant amount exercised. + References No definition available. + Details
Name: | spro_PotentialGrantAmountExercised
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Proceeds from government contract + References No definition available. + Details
Name: | spro_ProceedsFromGovernmentContract
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_BiomedicalAdvancedResearchAndDevelopmentAuthorityAndDefenseThreatReductionAgencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_BiomedicalAdvancedResearchAndDevelopmentAuthorityAndSperosAchievementOfSpecifiedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramsAndJointWarfighterMedicalResearchProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_SPRTwoZeroSixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spro_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_BasePeriodContractsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OptionIndexedToIssuersEquityTypeAxis=spro_FirstOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OptionIndexedToIssuersEquityTypeAxis=spro_SecondOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spro_DefenseThreatReductionAgencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=spro_NiaidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=spro_SperoCantabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=spro_CantabAntiInfectivesLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ShareRepurchaseProgramAxis=spro_CantabAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_OptionPeriodContractsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |